Vertex Pharmaceuticals INC / Ma Form 4 insider transactions

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reported selling 54 shares of common stock on May 15, 2024, under a pre-arranged trading plan.

Director Jennifer Schneider acquired 922 shares of Vertex Pharmaceuticals common stock through a restricted stock unit award on May 15, 2024.

EVP Edward Morrow Atkinson III reports acquisition of 14,112 Vertex Pharmaceuticals shares due to performance stock unit vesting, followed by a disposal of 14,112 shares.

Director Suketu Upadhyay reports acquisition and disposition of Vertex Pharmaceuticals stock and deferred stock units on May 1, 2024.

Director Nancy Thornberry reports acquisition and disposal of Vertex Pharmaceuticals stock and stock options on May 1, 2024.

Bruce I. Sachs, a director at Vertex Pharmaceuticals, acquired 3,142 stock options at a price of $399.71 on May 1, 2024.

Director Diana McKenzie reports acquisition and disposition of Vertex Pharmaceuticals common stock and deferred stock units on May 1, 2024.

Michel Lagarde, a director at Vertex Pharmaceuticals, acquired 3,142 stock options at an exercise price of $399.71 on May 1, 2024.

Director Terrence C. Kearney acquired 3,142 stock options in Vertex Pharmaceuticals on May 1, 2024, at an exercise price of $399.71.

Director Alan M. Garber acquired 3,142 stock options in Vertex Pharmaceuticals on May 1, 2024.

Director Lloyd Carney of Vertex Pharmaceuticals acquired 1,001 shares of common stock on May 1, 2024, through a restricted stock unit award.

Director Sangeeta N. Bhatia of Vertex Pharmaceuticals reports acquisition and disposal of company stock on May 1st and 2nd, 2024, respectively.

Director Bruce Sachs acquired deferred stock units representing common stock in Vertex Pharmaceuticals.

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the acquisition and disposal of company stock on April 1st and 2nd, 2024.

Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, reported disposing of 3,309 shares of common stock on February 23, 2024, to cover tax obligations.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, reports the acquisition and disposal of company stock.

Amit Sachdev, EVP Chief Patient & External Affairs Officer at Vertex Pharmaceuticals, reports the disposition and acquisition of company stock.

Reshma Kewalramani, CEO of Vertex Pharmaceuticals, disposed of 9,386 shares of common stock on February 23, 2024, to cover tax obligations.

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reported the disposal of 3,309 shares of common stock on February 23, 2024.

EVP Edward Morrow Atkinson III sold 883 shares of Vertex Pharmaceuticals common stock at $425.70 per share on February 26, 2024, according to a Form 4 filing with the SEC.

Stuart Arbuckle, EVP and COO of Vertex Pharmaceuticals, reported the disposition of shares to cover tax obligations and a sale of shares under a pre-arranged trading plan.

Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals, reports the disposition of common stock on February 23 and 26, 2024.

David Altshuler, EVP of Global Research and CSO at Vertex Pharmaceuticals, reports the disposition of company stock on February 23 and 26, 2024, according to a Form 4 filing.